Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer

Detalles Bibliográficos
Autor principal: and Alternative Medicine, Evidence-Based Complementary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Retraction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307265/
https://www.ncbi.nlm.nih.gov/pubmed/37388035
http://dx.doi.org/10.1155/2023/9879023
_version_ 1785066006570336256
author and Alternative Medicine, Evidence-Based Complementary
author_facet and Alternative Medicine, Evidence-Based Complementary
author_sort and Alternative Medicine, Evidence-Based Complementary
collection PubMed
description
format Online
Article
Text
id pubmed-10307265
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-103072652023-06-29 Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer and Alternative Medicine, Evidence-Based Complementary Evid Based Complement Alternat Med Retraction Hindawi 2023-06-21 /pmc/articles/PMC10307265/ /pubmed/37388035 http://dx.doi.org/10.1155/2023/9879023 Text en Copyright © 2023 Evidence-Based Complementary and Alternative Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Retraction
and Alternative Medicine, Evidence-Based Complementary
Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
title Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
title_full Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
title_fullStr Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
title_full_unstemmed Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
title_short Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
title_sort retracted: efficacy, safety, and tumor marker inhibition of apatinib combined with conventional chemotherapy regimens for patients with advanced triple-negative breast cancer
topic Retraction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307265/
https://www.ncbi.nlm.nih.gov/pubmed/37388035
http://dx.doi.org/10.1155/2023/9879023
work_keys_str_mv AT andalternativemedicineevidencebasedcomplementary retractedefficacysafetyandtumormarkerinhibitionofapatinibcombinedwithconventionalchemotherapyregimensforpatientswithadvancedtriplenegativebreastcancer

Ejemplares similares